Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

358.60DKK
10:59am EDT
Change (% chg)

kr.-10.60 (-2.87%)
Prev Close
kr.369.20
Open
kr.365.00
Day's High
kr.365.30
Day's Low
kr.357.80
Volume
2,943,296
Avg. Vol
2,720,531
52-wk High
kr.415.00
52-wk Low
kr.244.50

NOVOb.CO

Chart for NOVOb.CO

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and... (more)

Overall

Beta: 1.22
Market Cap(Mil.): kr.761,498.62
Shares Outstanding(Mil.): 2,062.56
Dividend: 5.00
Yield (%): 1.35

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 30.85 35.92 36.12
EPS (TTM): 11.97 -- --
ROI: 75.61 15.30 14.76
ROE: 82.48 15.87 15.63
Search Stocks

Novo Nordisk to buy two private pharma research firms

COPENHAGEN - Novo Nordisk said on Thursday it has agreed to buy two private biopharmaceutical research companies specializing in diabetes Calibrium LLC and MB2 LLC.

27 Aug 2015

Novo to begin Phase III trial of oral diabetes treatment

COPENHAGEN - Novo Nordisk said on Wednesday it would begin a Phase III trial of its treatment for diabetes that could be taken orally rather than by injection after "encouraging" results in previous trials.

26 Aug 2015

UPDATE 1-Novo to begin Phase III trial of oral diabetes treatment

COPENHAGEN, Aug 26 - Novo Nordisk said on Wednesday it would begin a Phase III trial of its treatment for diabetes that could be taken orally rather than by injection after "encouraging" results in previous trials.

26 Aug 2015

Novo to begin Phase III trial of oral diabetes treatment

COPENHAGEN, Aug 26 - Novo Nordisk said on Wednesday it would begin a Phase III trial of its treatment for diabetes that would be taken orally rather than by injection after "encouraging" results in previous trials.

26 Aug 2015

BRIEF-Genmab in license agreement with Novo Nordisk

* Enters commercial license agreement with Novo Nordisk for Duobody technology

14 Aug 2015

Novo Nordisk's Victoza sales up despite price pressure and China slowdown

COPENHAGEN - Strong sales of diabetes drug Victoza proved a bright spot for Denmark's Novo Nordisk in a second quarter hit by price pressures in the United States and declining sales in China.

06 Aug 2015

China gets tougher for Western drugmakers

LONDON - The Chinese market is getting tougher for Western pharmaceutical companies as Beijing bears down on a rising healthcare bill and prices come under pressure.

06 Aug 2015

China gets tougher for Western drugmakers

LONDON, Aug 6 - The Chinese market is getting tougher for Western pharmaceutical companies as Beijing bears down on a rising healthcare bill and prices come under pressure.

06 Aug 2015

UPDATE 2-Novo Nordisk's Victoza sales up despite price pressure and China slowdown

* Shares down 2 pct after initial rise to record high (Adds CEO, analyst, details)

06 Aug 2015

Novo Nordisk impacted by U.S. price pressure in H1 -CEO

COPENHAGEN, Aug 6 - Novo Nordisk, the world's largest insulin maker, was impacted by price pressure in the United States in the first half of 2015, its chief executive said.

06 Aug 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks